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Abstract
Background: Mesenchymal stem cells (MSCs) have been widely proven effective for therapeutic angiogenesis in
ischemia animal models as well as clinical vascular diseases. Because of the invasive method, limited resources,
and aging problems of adult tissue-derived MSCs, more perinatal tissue-derived MSCs have been isolated and
studied as promising substitutable MSCs for cell transplantation. However, fewer studies have comparatively
studied the angiogenic efficacy of MSCs derived from different tissues sources. Here, we evaluated whether the
in-situ environment would affect the angiogenic potential of MSCs.
Methods: We harvested MSCs from adult bone marrow (BMSCs), adipose tissue (AMSCs), perinatal umbilical cord
(UMSCs), and placental chorionic villi (PMSCs), and studied their “MSC identity” by flow cytometry and in-vitro
trilineage differentiation assay. Then we comparatively studied their endothelial differentiation capabilities and
paracrine actions side by side in vitro.
Results: Our data showed that UMSCs and PMSCs fitted well with the minimum standard of MSCs as well as
BMSCs and AMSCs. Interestingly, we found that MSCs regardless of their tissue origins could develop similar
endothelial-relevant functions in vitro, including producing eNOS and uptaking ac-LDL during endothelial
differentiation in spite of their feeble expression of endothelial-related genes and proteins. Additionally, we
surprisingly found that BMSCs and PMSCs could directly form tubular structures in vitro on Matrigel and their
conditioned medium showed significant proangiogenic bioactivities on endothelial cells in vitro compared
with those of AMSCs and UMSCs. Besides, several angiogenic genes were upregulated in BMSCs and PMSCs
in comparison with AMSCs and UMSCs. Moreover, enzyme-linked immunosorbent assay further confirmed that
BMSCs secreted much more VEGF, and PMSCs secreted much more HGF and PGE2.
Conclusions: Our study demonstrated the heterogeneous proangiogenic properties of MSCs derived from
different tissue origins, and the in vivo isolated environment might contribute to these differences. Our study
suggested that MSCs derived from bone marrow and placental chorionic villi might be preferred in clinical
application for therapeutic angiogenesis.
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Background
Mesenchymal stem cells (MSCs) are able to self-renew
and differentiate into a lineage of mesenchymal cells,
such as adipocytes, osteocytes, and chondrocytes. Be-
sides, they are of low immunogenicity and can exert po-
tent immunosuppression on HLA-mismatched PBMCs,
which make them ideal candidates for cell therapy and
tissue engineering [1]. Moreover, MSCs have been widely
reported to exert angiogenesis in in-vitro and in-vivo ex-
periments [2]. Also, human bone marrow-derived MSCs
(BMSCs) have been proven effective in clinical application
for therapeutic angiogenesis in patients with critical limb
ischemia [3]. Because of their favorite angiogenic proper-
ties, MSCs are attractive in clinical cell therapy and tissue
engineering for ischemia disease treatment [4].
MSCs were first isolated from bone marrow in 1976
[5], and other tissue-derived MSCs were then later har-
vested in succession. During the last decades, MSCs
derived from perinatal tissues [6], including umbilical
cord blood, umbilical cord, and placenta, have attracted
attention because of their noninvasive isolation methods
and minimal ethical issues. Moreover, perinatal tissue-
derived MSCs are young cells without higher possibilities
of incorporated mutation in comparison with adult
tissue-derived MSCs [6].
Many studies have comparatively analyzed the differ-
ential properties and biological functions of MSCs de-
rived from perinatal and adult tissues, including their
molecule profile [7], tridifferentiation potentials [8], pro-
liferation/clonogenic formation capacities [9], immuno-
modulatory functions [10], and hematopoietic support
abilities [11]. However, fewer studies have so far investi-
gated their angiogenic differences. Previous studies have
shown that both adult BMSCs and adipose tissue-derived
MSCs (AMSCs) could induce remarkable therapeutic
angiogenesis [12]. Umbilical cord-derived MSCs (UMSCs)
and placental chorionic villi-derived MSCs (PMSCs) have
also been reported to display angiogenic activity in in-
vitro and in-vivo experiments [13]. However, under the
same culture conditions, do these perinatal MSC popula-
tions have similar angiogenic effects as the typical adult
BMSCs and AMSCs? Does the in-situ environment of
MSCs affect their angiogenic properties? Is there any in-
fluence of the development stage on their angiogenic
functions? To answer these questions, we designed this
project and comparatively analyzed the angiogenic differ-
ences of BMSCs, AMSCs, UMSCs, and PMSCs.
Methods
Cell culture
The study was approved by the Ethical Committee and
the Institutional Review Board of the Chinese Academy
of Medical Science & Peking Union Medical College.
Bone marrow was collected from healthy volunteers in
the Blood Diseases Hospital. BMSCs were isolated fol-
lowing the protocol described previously [14]. AMSCs,
UMSCs, and PMSCs at passage 1 were supplied by the
Cell Products of National Engineering Research Center
(http://www.amcellgene.com) [15, 16]. Additionally, one
pair of UMSCs and PMSCs that derived from the same
donor was used. All volunteers provided informed con-
sent. BMSCs, AMSCs, UMSCs, and PMSCs were cultured
in the same standard culture condition. The standard
complete culture medium for MSCs was DMEM/F12
(DF12; Gibco, Grand Island, NY, USA), 10 % fetal bo-
vine serum (FBS; HyClone), 2 mM glutamine (Sigma,
St. Louis, MO, USA), 100 U/ml penicillin-streptomycin
(P/S; Invitrogen, Carlsbad, CA, USA), and 10 ng/ml epi-
dermal growth factor (EGF; Peprotech). Human umbilical
vein endothelial cells (HUVECs) were harvested by digest-
ing umbilical cord vein for 15 minutes at 37 °C. HUVECs
were cultured in Endothelial Growth Medium-2MV
(EGM-2MV; Lonza, Walkersville, MD, USA), and
HUVECs at passage 3~5 were used for experiments.
Endothelial differentiation
Cells were seeded on Matrigel (1:100 dilution; BD Bio-
science, Bedford, MA, USA) precoated flasks, and cultured
with EGM2-MV supplemented with 50 ng/ml VEGF
(Prepotech) [17] for 2 weeks. Endothelial differentiation
medium was changed twice a week. Cells cultured in
MSC complete medium were used as the control. Cells
with or without endothelial differentiation were then har-
vested, and the expression of endothelial-related genes was
independently tested by RT-PCR and immunostaining.
Real-time PCR
Endothelial-related genes were respectively tested on
undifferentiated and differentiated MSCs, and their rela-
tive expression level in undifferentiated MSCs was nor-
malized to 1; thus the fold-change in gene expression of
differentiated MSCs was calculated as 2–△△CT. Add-
itionally, to comparatively analyze the expression level
of angiogenic cytokines on BMSCs, AMSCs, UMSCs,
and PMSCs, RT-PCR was also performed. The relative
expression level of the candidate gene in particular
BMSCs or PMSCs was normalized to 1, and its relative
expression fold in other cells was shown as 2–ΔΔCT. The
real-time PCR was performed as follows: total RNA was
extracted using the E.Z.N.A. Total RNA Kit I (OMEGA,
Norcross, GA, USA), and cDNA was then synthesized
by using the MLV RT Kit (Invitrogen). The SYBR Green
detection method was employed, and the Applied Bio sys-
tem 7900 or 7300 Real-Time PCR System (Foster City,
CA, USA) was used. Each sample was performed in tripli-
cate (n = 3–5). Primers involved are listed in Additional file
1: Table S1.
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Immunostaining
EC-differentiated MSCs were harvested and seeded at
2 × 104 cells/cm2 in glass-bottom cell culture dishes (NEST)
overnight. Cells were first fixed with 4 % paraformaldehyde
(PFA) for 15 minutes. After permeabilization with 0.25 %
Triton X-100 solution (Sigma) for 30 minutes, the non-
specific epitope of cells was blocked by 0.2 % albumin
bovine V for 30 minutes. The cells were then incubated
with mouse anti-human von Willebrand Factor (vWF,
1:100 dilution; Abcam, Cambridge, MA, USA) or rabbit
anti-human eNOS antibodies (1:100 dilution; Abcam)
for 60 minutes, followed by staining with FITC-
conjugated anti-rabbit or anti-mouse antibodies (1:100
dilution; Invitrogen, Molecular Probes) for 30 minutes.
Cells stained with FITC-conjugated anti-mouse or anti-
rabbit IgG alone served as the control. Finally, cells were
stained with DAPI for 5 minutes, fixed with 2 % PFA, and
then photographs were taken by PerkinElmer UltraVIEW
Vox confocal microscope (PerkinElmer, Waltham, MA,
USA) under × 200 magnification.
Acetylated low-density lipoprotein-uptaking assay
To assess whether cells after endothelial differentiation
developed the endothelial-specific function in terms of
uptaking acetylated low-density lipoprotein (ac-LDL),
the acLDL-uptaking assay was performed. We harvested
EC-differentiated MSCs and seeded them on small culture
dishes with a glass bottom (NEST). After overnight incu-
bation in serum-free culture medium, cells were cultured
in fresh complete medium with 10 μg/ml Dil-acLDL (Invi-
trogen) for 4 hours. Later, cells were washed twice with
PBS and fixed with 4 % PFA following DAPI staining.
HUVECs were used as positive control. Photographs
were taken using a PerkinElmer UltraVIEW Vox con-
focal microscope.
Conditioned medium preparation
MSCs were plated at 4 × 104 cells/cm2 in a T25 flask over-
night. After washing twice with PBS, cells were cultured
with 10 ml EBM2 (Lonza) for another 2 days. Their condi-
tioned media (CMs) were then collected, centrifuged at
400 × g for 10 minutes to remove the cell debris, filtered
through a 0.2 μm filter (Pall Corporation, Ann Arbor, MI,
USA), and frozen at –80 °C for further studies. MSCs
derived from three donors were used.
In-vitro Matrigel tube formation assay
Direct Matrigel tube formation assay
To investigate their angio-vasculogenic capacities [18],
BMSCs, AMSCs, UMSCs, and PMSCs were collected and
seeded directly on a Matrigel (BD Bioscience) precoated
96-well plate at 2 × 104 cells/well in MSC complete
medium. Photographs were taken using the microscope
(Olympus, Melville, NY, USA) after 12 hours of incubation
(scale bar = 500 μm). Tube numbers in each well were
counted and each sample was performed in triplicate
(BMSCs, n = 2; AMSCs, UMSCs, and PMSCs, n = 3).
Indirect Matrigel tube formation assays
To better study the paracrine action of BMSCs, AMSCs,
UMSCs, and PMSCs, we used their CMs to incubate
endothelial cells and further assessed their trophic effects
on the angiogenic function of endothelial cells. CMs sup-
plemented with 2 % FBS, EBM2 supplemented with 2 %
FBS (served as the negative control), and EGM2-MV
(contained plentiful cytokines and 2 % FBS, served as the
positive control) were used to culture endothelial cells for
9 hours, respectively. Endothelial cells were seeded on
Matrigel at 2 × 104 cells/well in a 96-well plate. Photo-
graphs were taken by microscope (scale bar = 500 μm).
Tube numbers in each well were counted, and the total
tube length and total tube area in each well were mea-
sured using ImageJ software (NIH, USA). Three donor-
derived CMs were used and each sample was performed
in duplicate.
Endothelial cell proliferation assay
To investigate the proproliferative effects of the secretion of
BMSCs, AMSCs, UMSCs, and PMSCs, endothelial cells
were incubated with different MSC population-derived
CMs. The endothelial cell proliferation was measured using
the Cell Counting Kit-8 (Dojindo, Rockville, MD, USA).
Endothelial cells were first seeded at 1.0 × 104 cells/well in a
96-well plate overnight. After gently removing the medium,
cells were washed twice with PBS, and then CMs supple-
mented with 2 % FBS, EBM2 supplemented with 2 % FBS
(served as the negative control), and EGM2-MV (served
as the positive control) were added to the cells for
another 48 hours. Each sample was performed in tripli-
cate. ΔOD450 indicated the final data after subtracting
the background.
Enzyme-linked immunosorbent assay
To determine the concentration of VEGF, HGF, bFGF,
and PGE2 in supernatants of MSCs, enzyme-linked
immunosorbent assays (ELISAs) were performed. The
48-hour supernatants of MSCs with an initial seeding
density of 20,000 cells/well in a 96-well plate were col-
lected for VEGF, HGF, and bFGF measurements, while
the 72-hour supernatants of MSCs with an initial density
of 105 cells/well in a six-well plate were collected for
PGE2 measurements. All of the supernatants were centri-
fuged at 400 × g for 10 minutes and then measured by
their corresponding ELISA kits. The ELISA kits for VEGF,
HGF, and bFGF were purchased from Neobioscience
Biotech (Shenzhen, China), and the PGE2 ELISA kit was
purchased from Cayman Chemicals. All of the procedures
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strictly followed the corresponding instructions. Superna-
tants derived from three donors were used.
Statistical analysis
Statistical analysis was performed by GraphPad Prism
6.0 software (Graph Pad Software, Inc., San Diego, CA,
USA). All data are shown as the mean ± SEM. One-way
ANOVA followed by Bonferroni multiple comparisons
was employed to determine the statistical significance.
Paired t test was used to analyze the endothelial gene
modification after endothelial differentiation. The result
was considered statistically significant if p < 0.05.
Results
Limited potentials of endothelial differentiation
Previous studies have shown that the endothelial differen-
tiation mechanism participates in MSC-mediated wound
healing [19]. To investigate their capabilities of endothelial
differentiation, BMSCs, AMSCs, UMSCs, and PMSCs
were harvested and induced into endothelial cells in vitro
for 2 weeks. The undifferentiated and differentiated MSCs
were then collected, and the endothelial gene expression
further comparatively analyzed. Data revealed that the
relative expression levels of CD31, CD34, Flt1, vWF,
VE-Cadherin (VEC), and Tie-2 were altered differently
in EC-differentiated MSCs in comparison with undiffer-
entiated cells; however, no statistical significance was
found (p > 0.05) (Fig. 1a). There was an increase in expres-
sion of CD31, CD34, vWF, and VEC in EC-differentiated
AMSCs, UMSCs, and PMSCs but a decreased expression
in EC-differentiated BMSCs. Similarly, Flt-1 was upregu-
lated in AMSCs and UMSCs but declined in BMSCs and
PMSCs after endothelial differentiation. Tie-2 expression
was raised to various degrees in BMSCs, AMSCs, and
PMSCs during endothelial differentiation, but with a
falloff in UMSCs. To better define the expression of
endothelial-related proteins and the unique functions
of cells after endothelial differentiation, an immuno-
staining assay [20, 21] and an acLDL-uptaking assay
[22] were performed respectively (Fig. 1b). Our data
showed that EC-differentiated MSCs weakly expressed
vWF and CD31 in contrast to the HUVECs (positive
control). However, MSCs produced eNOS and devel-
oped acLDL uptaking capacities to some extent after
endothelial differentiation, which were special functions
of endothelial cells. This observation indicated that MSCs
could develop some properties of endothelial cells under
appropriate conditions.
Heterogeneous angio-vasculogenic capacities of BMSCs,
AMSCs, UMSCs, and PMSCs on in-vitro Matrigel tube
formation assay
The in-vitro Matrigel tube formation assay was generally
used as the first screen to test whether a compound
might participate in angiogenesis [23]. MSCs were re-
ported to spontaneously generate 3-D capillary-like struc-
tures on Matrigel in vitro [18, 24]. To determine their
angio-vasculogenic capacities, BMSCs, AMSCs, UMSCs,
and PMSCs were directly seeded on Matrigel and the tube
formation was observed after 12 hours of incubation.
Interestingly, intact tube structures were seen in the
BMSC and PMSC groups rather than in the groups of
AMSCs and UMSCs (Fig. 2a). Tube numbers in the
BMSC and PMSC groups were 11.65 ± 2.92 and 6.49 ±
1.18, respectively, much higher than those in the AMSC
and UMSC groups (0.91 ± 0.76 and 0.41 ± 0.20, p < 0.05)
(Fig. 2b). These observations indicated that BMSCs and
PMSCs had better angio-vasculogenic capacities in com-
parison with UMSCs and AMSCs.
BMSCs and PMSCs displayed potent paracrine actions on
endothelial cells
Secreted factors from MSC populations have been re-
ported to significantly enhance the proliferation and
function of endothelial cells in vitro [25]. To compara-
tively analyze their paracrine actions, we respectively
used BMSCCM, AMSCCM, UMSCCM, and PMSCCM to
culture endothelial cells and comparatively analyzed the
effects on the proliferation and tube formation capacity
of endothelial cells. We found that BMSCCM and PMSCCM
could significantly promote endothelial cell proliferation
(1.23 ± 0.06 and 1.24 ± 0.06) in contrast to AMSCCM and
UMSCCM (0.84 ± 0.02 and 0.85 ± 0.07; n = 3, *p < 0.05
and **p < 0.01) during 48 hours of incubation. The pro-
proliferative effects of BMSCCM and PMSCCM were
similar to EGM2-MV (the complete endothelial cell
culture medium containing plentiful growth factors),
and much greater than EBM2 (0.74 ± 0.03, p < 0.01).
However, AMSCCM and UMSCCM did not reveal such
promotion on the mitosis of endothelial cells compared
with the EBM2 group (n = 3, p > 0.05). Hence, we sup-
posed that BMSCs and PMSCs secreted many more
proproliferative factors than AMSCs and UMSCs (Fig. 3a).
In addition, we used BMSCCM, AMSCCM, UMSCCM,
and PMSCCM to culture endothelial cells to test whether
the secreted factors would affect the tube formation cap-
acities of endothelial cells on Matrigel in vitro. Interest-
ingly, CMs significantly promoted tube formation of
endothelial cells by contrast with EBM2, in which no
intact tube structure was observed (Fig. 3b). Similarly,
we found BMSCCM and PMSCCM significantly promoted
endothelial cells to generate intact tube structures, which
numbered 30.33 ± 3.59 and 31.17 ± 2.18, respectively,
much greater than those in the group of AMSCCM and
UMSCCM (17.50 ± 2.09 and 18.50 ± 1.38; n = 3, *p < 0.05
and **p < 0.01) (Fig. 3c). The total tube area and total tube
length were also greater in the BMSCCM and PMSCCM
groups (BMSCCM: 11.90 ± 1.46 and 75.93 ± 8.83; PMSCCM:
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Fig. 1 Endothelial differentiation potential of different MSC populations is heterogeneous and limited. a Relative expression levels of CD31, CD34,
Flt1, vWF, VE-cadherin, and Tie-2 were investigated in undifferentiated and EC-differentiated BMSCs, AMSCs, UMSCs, and PMSCs. The candidate
gene expression in undifferentiated MSCs was normalized to 1, and the relative fold-change in the corresponding EC-differentiated cells was shown as
2–ΔΔCT. BMSCs derived from two donors, and AMSCs, UMSCs, and PMSCs derived from three individuals were used. b Confocal microscope was used
to investigate the expression of vWF and CD31 in EC-differentiated MSCs and HUVECs. To identify whether the EC-differentiated cells displayed similar
functions to endothelial cells, immunostaining of eNOS and acLDL-uptaking assay were respectively performed. All photographs were captured
at × 200 magnification. HUVECs served as positive control. MSC mesenchymal stem cells, HUVEC human umbilical vein endothelial cells, BMSC
bone marrow-derived MSCs, AMSC adipose tissue-derived MSCs, UMSC umbilical cord-derived MSCs, PMSC placental chorionic villi-derived
MSCs, vWF von Willebrand Factor, eNOS endothelial nitric oxide synthase, acLDL acetylated-low density lipoprotein
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13.39 ± 0.70 and 83.36 ± 4.73) than in the AMSCCM and
UMSCCM groups (AMSCCM: 7.20 ± 1.12 and 45.05 ± 5.39;
UMSCCM: 9.03 ± 0.39 and 51.16 ± 2.36; n = 3, *p < 0.05,
**p < 0.01 and ***p < 0.001) (Fig. 3d, e). These results in-
dicated that the secretion of BMSCs and PMSCs con-
tained more bioactive factors than that of AMSCs and
UMSCs in the enhancement of the vasculogenic func-
tions of endothelial cells.
PMSCs and BMSCs expressed higher levels of angiogenic
factors
Cytokines secreted by MSCs played vital roles in the
process of MSC-mediated angiogenesis [26]. Referring to
the previous research [25, 26], we selected a panel of
candidates, including VEGF-A,VEGF-C, HGF, bFGF, NGF,
angiogenin (ANG), TGF-β, IL-6 [27], IL-8 [28], IL-1α
[29], IL-1β [30], and Cox-2 [31], and tested their relative
expression levels in different MSC populations. One-
way ANOVA analysis revealed that the comparison of
VEGF-A, HGF, bFGF, NGF, IL-6, IL-8, TGF-β, IL-1α, IL-
1β, and Cox-2 expression among different MSC types
was statistically significant (p < 0.05); while the expres-
sion of VEGF-C, ANG, and TGF-β in different MSC
populations showed no significant difference (p > 0.05).
Of note, the relative expression levels of HGF, bFGF, IL-6,
IL-8, IL-1α, IL-1β, and Cox-2 in PMSCs were compara-
tively higher than that in other MSC populations. Be-
sides, BMSCs expressed a comparatively higher level of
VEGF-A, NGF, and ANG (Fig. 4a). Therefore, PMSCs,
as well as BMSCs, were superior to AMSCs and UMSCs
for angiogenic gene expression.
As previous studies have reported, bFGF, VEGF, HGF,
and PGE2 could significantly promote angiogenesis
[32, 33]. To further explore the secretion of angiogenic-
related factors, we assessed the concentrations of bFGF,
VEGF, HGF, and PGE2 in supernatants of different MSC
populations via ELISA. Data showed that MSCs secreted a
lower level of bFGF under normal conditions, which
was about 36–69 pg/ml. The concentrations of VEGF
in the supernatants of BMSCs and PMSCs were 882.7 ±
55.27 pg/ml and 721.4 ± 120.4 pg/ml, respectively, much
higher than that in UMSC-derived supernatants (77.16 ±
77.16 pg/ml; n = 3, p < 0.01), and a medial level of VEGF
(486.3 ± 111.8 pg/ml) was found in AMSC supernatant.
Furthermore, the HGF concentration in supernatants
of perinatal tissue-derived MSCs (PMSCs: 9466 pg/ml;
UMSCs: 7694 pg/ml) was significantly higher than
that in adult tissue-derived MSCs (BMSCs: 119 pg/ml;
AMSCs: 1589 pg/ml) (n = 3, p < 0.05; Fig. 4b), which
was in accordance with our RT-PCR results and also
agreed with the study by Amable et al. [34]. Addition-
ally, the PGE2 concentration in supernatants of PMSC
(32,628 pg/ml) was significantly higher than that in other
MSC types (BMSC: 2074 pg/ml, AMSC: 337.9 pg/ml;
UMSC: 3603 pg/ml; n = 3, p < 0.05).
To further study whether the in-situ environment
would affect the angiogenic properties of MSCs, we eval-
uated the relative expression of IL-8, HGF, TGF-β, IL-1α,
IL-1β, IL-6, and Cox-2 in one donor-derived UMSC and
PMSC by RT-PCR. Our results indicated that PMSCs
expressed a remarkably higher level of IL-8, HGF, IL-1α,
IL-1β, IL-6, and Cox-2 than UMSCs (Fig. 4c). Thus, con-
sidering the possible impact of their different isolated
environment, placental chorionic villi would be a favorite
tissue source for isolating MSCs with superior angiogenic
cytokine expression.
Discussion
In the present study, we performed a parallel compari-
son of angiogenic potentials of MSCs derived from adult
tissues (bone marrow and adipose tissue) and perinatal
tissues (umbilical cord and placental chorionic villi). Cells
were isolated from different in-situ environments as well
as distinct developmental stages, which we hypothesized
Fig. 2 MSCs derived from different tissue sources display distinct tube formation capacities on Matrigel in vitro. MSCs were seeded on Matrigel in
vitro at 2 × 104 cells/well. MSCs could form tube-like structures on Matrigel temporarily (a). Representative photographs were taken after
12 hours of incubation (scale bar = 500 μm). b Numbers of tube structures were counted and analyzed (BMSC, n = 2; AMSC, UMSC, and PMSC,
n = 3). Each sample was performed in triplicate (*p < 0.05, ****p < 0.0001). MSC mesenchymal stem cells, BMSC bone marrow-derived MSCs,
AMSC adipose tissue-derived MSCs, UMSC umbilical cord-derived MSCs, PMSC placental chorionic villi-derived MSCs
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might affect their angiogenic properties. After verifying
the phenotype and trilineage differentiation, we com-
paratively studied their angiogenic properties from two
aspects: endothelial differentiation and paracrine activ-
ity. MSCs regardless of their tissue origins have limited
capacities to transform into endothelial cells; however, the
CM of BMSCs and PMSCs showed stronger proangiogenic
activities on endothelial cells in vitro than that of AMSCs
and UMSCs.
The endothelial differentiation capacity of MSCs re-
mains controversial. Aguilera et al. [20] demonstrated that
Wharton’s jelly-derived mesenchymal cells expressed
high levels of endothelial markers (CD31 and KDR)
and also synthesized NO after 30 days of endothelial
Fig. 3 Conditioned medium (CM) of BMSCs, AMSCs, UMSCs, and PMSCs exerts various proangiogenic effects on endothelial cells in vitro. CMs
were generated from 106 cells after 48 hours of incubation with EBM2. CMs supplemented with 2 % FBS, EBM2 supplemented with 2 % FBS
(negative control), and EGM2-MV (containing 2 % FBS, positive control) were used to culture endothelial cells and further comparatively analyze
their effects on endothelial cell proliferation. a Similar to EGM2-MV, BMSCCM and PMSCCM significantly promoted endothelial cell proliferation in
comparison with EBM2 after 48 hours of culture; however, AMSCCM and UMSCCM did not produce such a promotion effect. Each sample was
performed in triplicate (n = 3, *p < 0.05, **p < 0.01). To determine the bioactivity of secreted factors from MSCs on endothelial cells, an in-vitro
Matrigel tube formation assay was performed. Representative photographs were taken after 9 hours of incubation (scale bar = 500 μm). b Number
of tube structures (c) was counted; total tube area (d) and total tube length (e) in each well were measured and analyzed using ImageJ software.
Each sample was performed in duplicate (n = 3, *p < 0.05, **p < 0.01, ***p < 0.001). MSC mesenchymal stem cells, BMSC bone marrow-derived
MSCs, AMSC adipose tissue-derived MSCs, UMSC umbilical cord-derived MSCs, PMSC placental chorionic villi-derived MSCs
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differentiation. Additionally, Ikhapoh et al. [35] and
Benavides et al. [21] respectively reported that BMSC
and amniotic fluid-derived stem cells were capable of
differentiation into endothelial cells. By contrast, Choi
et al. [36] reported that Wharton’s jelly-derived mesen-
chymal stromal/stem cells did not express endothelial
specific markers (VEGFR2, Tie2, vWF, CD31, and VE-
cadherin) when they were cultured in endothelial in-
duction medium. Partially agreeing with their results,
our data showed that EC-differentiated MSCs were not
sufficient to transform into mature endothelial cells
because of their very low expression levels of CD31.
However, endothelial differentiation did prime MSCs
by upregulating some endothelial-related genes and de-
veloping endothelial-special functions, such as eNOS
generation and acLDL-uptaking capacity, which was in
accordance with the study by Janeczek Portalska et al.
[37]. Although all of the cells were cultured with endo-
thelial differentiation medium under the same condition,
an inconsistent change of endothelial-related genes was
seen in our results, which might be due to the wide inter-
donor variability. A similar result was also seen in the
study of Kim et al. [18]. Because the shear stress [38] as
well as the small molecule or microgravity [39] could en-
hance the efficiency of MSC endothelial differentiation, a
modified protocol might help MSCs transform into endo-
thelial cells in vitro.
In-vivo MSC transplantation studies demonstrated
that very few engrafted MSCs remained several weeks
post transplantation. Wu et al. [19] reported that 27 %
of transplanted MSCs engrafted into the wounded skin
but only 2.5 % cells remained 28 days post administra-
tion. Moon et al. [40] demonstrated that less than 1 %
engrafted AMSCs were incorporated into the host vas-
cular structures 4 weeks after cell transplantation. In
view of the clinical application of MSCs, endothelial
differentiation may not be the principal mechanism of
MSC-mediated regeneration. Meanwhile, accumulating
evidence suggested that the bioactive secretion of MSCs
was the dominant reason for their therapeutic benefits
[26]. Kwon et al. [33] demonstrated that the CM of hu-
man MSCs significantly improved the in-vitro angiogenic
activity of endothelial cells and promoted the blood res-
toration in mice with hind-limb ischemia. Consistently,
our result also confirmed the strong proangiogenic action
of MSCs via in-vitro paracrine assays.
In addition, many studies have indicated heterogeneous
angiogenic gene expression in different MSC types. For
example, Hsiao et al. [25] demonstrated a similar mRNA
expression level of VEGF-A, bFGF, HGF, and NGF in
BMSCs and AMSCs. Amable et al. [34] reported that
differential secretion was found in BMSCs, AMSCs, and
Wharton’s Jelly-derived MSCs, which was consistent with
our result, especially on VEGF and HGF secretion. Simi-
larly, Rehman et al. [41], Kandel and Pittenger [42], and
Bronckaers et al. [26] also demonstrated a varying para-
crine action in different tissue-derived MSCs. Here, our
study determined a distinct angiogenic cytokine expres-
sion by different MSC types, particularly the secretion of
VEGF, HGF, and PGE2. Previous studies have shown that
VEGF [43], HGF [44], and PGE2 [32] were important
angiogenic cytokines that could significantly promote the
growth and tube formation of endothelial cells. Because
the different paracrine actions may lead to distinct thera-
peutic outcomes, some tissue-derived MSC populations
with potent paracrine activity should be preconsidering
cell banking and clinical application. Our study showed
heterogeneous paracrine behaviors of different MSC types,
which may indicate potential for tissue source selection of
MSCs for clinical therapeutic angiogenesis. Nevertheless,
the in-vivo pro-angiogenic properties of different MSC
types still need further exploration.
Our FACS results showed distinct vascular cell adhe-
sion molecular-1 (VCAM-1) expression on different
MSC types. VCAM-1, also known as CD106, is exten-
sively expressed on endothelial cells [45] and some
stromal cells in a particular niche, such as the vascular
niche [46] and the hematopoietic niche [47, 48]. Wang
et al. [49] described that MSCs pretreated with cyto-
kines (IL-1β and TNF-α) upregulated VCAM-1 expres-
sion and revealed an improved treatment effect on
cardiovascular ischemia. Recently, our group reported
that VCAM-1+ placental chorionic villi-derived MSCs
secreted abundant angiogenic cytokines and displayed
(See figure on previous page.)
Fig. 4 Gene and protein expression of selected paracrine factors in different MSC populations. a Relative mRNA expression of selected angiogenic
cytokines was assessed, including VEGF-A, VEGF-C, HGF, bFGF, NGF, ANG, TGF-β, IL-6, IL-8, IL-1α, IL-1β, and Cox-2. The relative expression level of the
candidate cytokine in one sample of BMSCs or PMSCs was normalized to 1, and all other samples for corresponding gene expression were shown as
2–ΔΔCT fold-change. Each sample was tested in triplicate (n = 3–5). b Concentrations of bFGF, VEGF, and HGF in 48-hour supernatants and the PGE2
concentration in 72-hour supernatants of BMSCs, AMSCs, UMSCs, and PMSCs were measured using corresponding ELISA kits (n = 3, *p < 0.05,
**p < 0.01). c The relative mRNA expression of IL-8, HGF, TGF-β, IL-1α, IL-1β, IL-6, and Cox-2 was separately tested on one donor-derived UMSC
and PMSC. The relative expression level of the candidate gene in UMSCs was normalized to 1, and the fold-change in PMSCs was expressed
as 2–ΔΔCT. To better show the different expression of angiogenic genes in UMSCs and PMSCs, data were shown in log2. MSC mesenchymal
stem cells, BMSC bone marrow-derived MSCs, AMSC adipose tissue-derived MSCs, UMSC umbilical cord-derived MSCs, PMSC placental chorionic
villi-derived MSCs, VEGF vascular endothelial growth factor, HGF hepatocyte growth factor, bFGF basic fibroblast growth factor, NGF nerve
growth factor, ANG angiogenin, TGF-β transforming growth factor beta, IL interleukin
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therapeutic angiogenesis on hind-limb ischemia nude
mice [50]. These studies indicated a possible correlation
between a higher VCAM-1 expression ratio on MSCs
and a better proangiogenic activity. Consistently, our
present study suggested that a better paracrine action
existed in MSC types with a higher VCAM-1 expres-
sion level, such as PMSCs and BMSCs.
In addition, BMSCs, AMSCs, UMSCs, and PMSCs are
respectively isolated from different in-vivo environments:
bone marrow and placental chorionic villi are abundant
with capillaries, adipose tissue is filled with adipocytes,
and umbilical cord contains not only blood vessels but
also Wharton’s Jelly (the tissue source of UMSCs). These
distinct in-vivo environments may affect the bioactivities
of MSCs. Konig et al. [51] demonstrated that placental
MSCs isolated from blood vessels were better than those
from avascular tissues on supporting endothelial cell func-
tions. Jeon et al. [52] reported that placenta-derived MSCs
retained a higher therapeutic efficacy than BMSCs and
AMSCs in the hind-limb ischemic disease model. More-
over, our RT-PCR results showed a higher angiogenic
cytokine expression in the same donor-derived PMSCs ra-
ther than UMSCs, which further indicated that the in-situ
environment but not the development status might have
some effect on the proangiogenic features of MSCs. On
the other hand, the in-vitro angiogenic features of MSCs
may reflect the characteristics of their different in-situ
environment to some extent.
Conclusions
In this study, we described the heterogeneous proangio-
genic features of MSCs derived from different tissue
sources, and further demonstrated that the in-vivo envir-
onment but not the development status might contribute
to their functional heterogeneity. Moreover, our study sug-
gested BMSCs and PMSCs might be preferred in clinical
application for vascular diseases due to their potent para-
crine actions.
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